SARM represents the Selective Androgen Receptor Modulator (an optional modulator of the male hormone receptor). Basically, they are analogous to anti-estrogen (tamoxifen) by acting on estrogen receptors and causing androgens to have a positive effect on the body.
While most SARM have relatively few side effects from male hormones, they have relatively little assimilation compared to substances such as testosterone or nadrolone.
SARM has been shown to increase fat-free muscle mass, bone mass and fat mass without significantly increasing estrogen and reducing fat mass or over-suppressing the hypothalamic pituitary gonad, and also suggests that the prostate, or flat- Not at all.
Ideally, SARM antagonizes androgenic organs (prostate) and acts strongly in “anabolic” organs (muscles and bones).
SARM was discovered in the 1940s when the chemical structure of testosterone molecules was modified. This first SARM is derived from a testosterone molecule and is therefore considered steroid. Today, however, pharmaceutical companies and other organizations are developing non-steroidal SARMs.
Today, we are finding more and more SARMs that are increasingly bioavailable and less toxic to the liver.
Although there are a number of SARMs under study in clinical trials, no one has progressed to IV but aims at monitoring their consumption in the general population and analyzing long-term effects, but it is sometimes intentional. When made and licensed as medicines, they can become controlled medicines because they are patented and costly. For the time being, SARM may be legally distributed for research and scientific purposes only.